NCT00460382View on ClinicalTrials.gov

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

PHASE2CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

September 30, 2009

Conditions

HIV Infections

Interventions

DRUG

raltegravir potassium

400 mg twice a day

DRUG

darunavir/ritonavir

2 pills of 300 mg twice a day

DRUG

etravirine

2 pills of 100 mg twice a day

DRUG

Optimized background regimen

NRTIs and or enfuvirtide (investigator choice)

Trial Locations (1)

59208

Hôpital Gustave Dron, Service Maladies Infectieuses, Tourcoing

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Janssen-Cilag Tibotec

UNKNOWN

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00460382 - Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses | Biotech Hunter | Biotech Hunter